Adherence to Oral Chemotherapy Research Grant
ONS Foundation Adherence to Oral Chemotherapy Research Grant (RE39)
Funded by Research Consortium Partner: GlaxoSmithKline. Additional funding from Novartis Pharmaceuticals Corporation and Celgene Corporation
Level of Funding
: Pilot or Feasibility Study: Up to $75,000
Research Grant: Up to $150,000
Purpose: Applications are invited for research proposals that address nursing interventions to promote and maintain adherence to oral chemotherapy. A major goal of the ONS Foundation is to provide funding to support the ONS Research Agenda. The agenda’s focus is on areas where gaps exist in the knowledge base for oncology nursing practice by building on previous research findings to move the science forward. Section F1 of the 2009-2013 ONS Research Agenda identifies specific priority adherence research areas.
Award: Pilot studies funded up to $75,000 and grants up to $150,000 will be awarded with a funding period of up to two years. First year funding will be available by January 2014. “No Cost Extensions” will not be available.
Eligibility: The principal investigator must be actively involved in some aspect of cancer patient care, education, or research and be PhD-prepared. Membership in ONS is not required for eligibility.
If you have further questions, please contact the ONS Foundation Research Department at firstname.lastname@example.org
Welcome to the Online ONS Foundation Adherence to Oral Chemotherapy Research Grant Application.
We have developed two instructional guides to assist you with your online application entry:
- An Online Submission Overview.
- A slide presentation with views of the application sections and instructions on each slide.
RE39-ONS Foundation Adherence to Oral Chemotherapy Research Grant Application Submission Website